Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways <i>via</i> off-VEGF signaling
Xiaoling Zhang, Yan Zhang, Yanan Jia, Tingting Qin, Cuicui Zhang, Yueya Li, Chengmou Huang, Zhujun Liu, Jing Wang, Kai Li
Abstract
activation of the TGFβ1 pathway and upregulation of CD105 expression. Anlotinib reverses the effects of bevacizumab by inhibiting the above signals.
Topics & Concepts
BevacizumabEndoglinUmbilical veinAngiogenesisCancer researchDownregulation and upregulationVascular endothelial growth factorReceptor tyrosine kinaseSignal transductionTransforming growth factorVascular endothelial growth factor AKinase insert domain receptorMedicineChemistryPharmacologyCell biologyBiologyEndocrinologyInternal medicineBiochemistryChemotherapyVEGF receptorsGeneCD34Stem cellIn vitroAngiogenesis and VEGF in CancerCancer, Hypoxia, and MetabolismTGF-β signaling in diseases